Real-world data for the use of emicizumab in haemophilia A patients with inhibitors - First nationwide report from Korea

被引：6
|
作者：
Hahn, Seung Min [1 ,2 ]
Han, Jung Woo [1 ,2 ]
Kim, Jin Seok [3 ]
Shim, Ye Jee [4 ]
Kim, Soyon [5 ]
Kim, Hugh Chul [5 ]
Park, Young Shil [6 ]
Lyu, Chuhl Joo [1 ,2 ,7 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea
[2] Yonsei Univ, Severance Hosp, Yonsei Canc Ctr, Dept Pediat Hematol Oncol,Coll Med, Seoul, South Korea
[3] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea
[4] Keimyung Univ, Dongsan Hosp, Dept Pediat, Sch Med, Daegu, South Korea
[5] Kim & Lees Internal Med Clin, Seoul, South Korea
[6] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Dept Pediat, Coll Med, Seoul, South Korea
[7] Yonsei Univ, Severance Hosp, Coll Med, Yonsei Canc Ctr,Dept Pediat Hematol Oncol, 50-1 Yonseiro, Seoul 03722, South Korea
来源：
HAEMOPHILIA | 2023年 / 29卷 / 04期
关键词：
PROPHYLAXIS;
D O I：
10.1111/hae.14819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1163 / 1166
页数：4
相关论文
共 50 条
  • [41] Real experience of prophylaxis with emicizumab in patients with congenital haemophilia A with and without FVIII inhibitors in the HCUVA
    Heredia Cano, Angela
    Garcia Candel, Faustino
    Sanchez Villalobos, Maria
    Poveda Garcia, Andrea
    Torchia Esteban, Marcos
    Ruiz Ruiz, Estela
    Sanchez Salas, Jose Antonio
    Navarro Almenzar, Begona
    Caracena Lopez, Sara
    Perez Laencina, Marta
    Blazquez Soto, Juan Antonio
    HAEMOPHILIA, 2024, 30 : 31 - 32
  • [42] A multicentre real-world data study to assess the bleeding rate and management of patients with haemophilia A and factor VIII inhibitors in Argentina
    Neme, Daniela
    Ramos Mejia, Isabel
    Elelhou, Ludmila
    Do Nascimento, Patricia
    Arrieta, Maria E.
    Cocca, Andrea
    Saenz, Victoria
    Davoli, Mauro
    BLOOD COAGULATION & FIBRINOLYSIS, 2021, 32 (08) : 564 - 571
  • [43] Real-world study: from real-world data to real-world evidence
    Wen, Yi
    TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
  • [44] Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
    Holstein, Katharina
    Le Quellec, Sandra
    Klamroth, Robert
    Batorova, Angelika
    Holme, Pal Andre
    Jimenez-Yuste, Victor
    Astermark, Jan
    HAEMOPHILIA, 2022, 28 (02) : 215 - 222
  • [45] Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database
    Lim, Jihye
    Kim, Hwa Jung
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [46] Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
    Liu, Guoqing
    Huang, Kun
    Li, Gang
    Zhen, Yingzi
    Li, Zhengping
    Chen, Zhenping
    Wu, Runhui
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [47] Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
    Kim, Soo Young
    Kim, Seok-Mo
    Chang, Hojin
    Kim, Bup-Woo
    Lee, Yong Sang
    Chang, Hang-Seok
    Park, Cheong Soo
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [48] BURDEN OF ILLNESS OF HAEMOPHILIA B PATIENTS USING DATA FROM CHESS II, A EUROPEAN REAL-WORLD DATA STUDY
    Young, L.
    Loftus, J.
    Chen, Y.
    Alvir, J.
    Chi, L.
    King, A.
    Winburn, I.
    HAEMOPHILIA, 2020, 26 : 94 - 95
  • [49] PROPHYLAXIS WITH EMICIZUMAB IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: DATA OF A PORTUGUESE CONGENITAL COAGULOPATHIES REFERENCE CENTRE
    Sousa, M.
    Vaz, C.
    Fernandes, S.
    Oliveira, M.
    Carvalho, M.
    Lopes, M.
    Koch, C.
    HAEMOPHILIA, 2021, 27 : 110 - 110
  • [50] Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
    Kim, Sung Eun
    Kim, Ji Yoon
    Park, Jeong A.
    Lyu, Chuhl Joo
    Hahn, Seung Min
    Han, Jung Woo
    Park, Young Shil
    BLOOD RESEARCH, 2024, 59 (01)
12345